Laverock Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.94M

  • Investors
  • 15

Laverock Therapeutics General Information

Description

Developer of a gene silencing platform designed to create programmable therapies for complex diseases. The company offers recoded microRNA-based gene control technology and therapeutic development capabilities, enabling biotechnology and healthcare organizations to develop targeted therapies with controlled gene expression and improved safety profiles.

Contact Information

Website
www.laverocktx.com
Formerly Known As
Skylark Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Apex Building
  • 6 Street Pancras Way
  • London NW1 0TB
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Apex Building
  • 6 Street Pancras Way
  • London NW1 0TB
  • England, United Kingdom

Laverock Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Laverock Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant $2.94M Completed Product Development
5. Accelerator/Incubator 01-Sep-2025 Completed Startup
4. Seed Round 30-Jun-2025 Completed Startup
3. Working Capital 27-Sep-2023 Completed Startup
2. Grant 01-Sep-2022 $836K Completed Startup
1. Seed Round 31-Aug-2022 Completed Startup
To view Laverock Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Laverock Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene silencing platform designed to create programmable therapies for complex diseases. The company offer
Drug Discovery
London, United Kingdom
29 As of 2025

Oxford, United Kingdom
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Laverock Therapeutics Competitors (93)

One of Laverock Therapeutics’s 93 competitors is Sitryx, a Venture Capital-Backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sitryx Venture Capital-Backed Oxford, United Kingdom
Carmine Therapeutics Venture Capital-Backed Cambridge, MA
Vir Biotechnology Formerly VC-backed San Francisco, CA
ArsenalBio Venture Capital-Backed South San Francisco, CA
Progenra Formerly VC-backed Malvern, PA
You’re viewing 5 of 93 competitors. Get the full list »

Laverock Therapeutics Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Laverock Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202410438-D0 Regulating gene expression Inactive 17-Jul-2024
GB-202410439-D0 Regulating gene expression Inactive 17-Jul-2024
GB-202307090-D0 Cell context-specific gene regulation using inhibitory rnas Inactive 12-May-2023
AU-2024208104-A1 Cell context-specific gene regulation using inhibitory rnas Pending 13-Jan-2023
EP-4649150-A1 Cell context-specific gene regulation using inhibitory rnas Pending 13-Jan-2023 C12N15/113
To view Laverock Therapeutics’s complete patent history, request access »

Laverock Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Laverock Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Grow London Accelerator/Incubator
Agronomics Venture Capital Minority
Calculus Capital PE/Buyout Minority
Eos Advisory Venture Capital Minority
Lilly USA Corporation Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

Laverock Therapeutics FAQs

  • When was Laverock Therapeutics founded?

    Laverock Therapeutics was founded in 2021.

  • Where is Laverock Therapeutics headquartered?

    Laverock Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Laverock Therapeutics?

    Laverock Therapeutics has 29 total employees.

  • What industry is Laverock Therapeutics in?

    Laverock Therapeutics’s primary industry is Drug Discovery.

  • Is Laverock Therapeutics a private or public company?

    Laverock Therapeutics is a Private company.

  • What is Laverock Therapeutics’s current revenue?

    The current revenue for Laverock Therapeutics is .

  • How much funding has Laverock Therapeutics raised over time?

    Laverock Therapeutics has raised $27.5M.

  • Who are Laverock Therapeutics’s investors?

    Grow London, Agronomics, Calculus Capital, Eos Advisory, and Lilly USA are 5 of 15 investors who have invested in Laverock Therapeutics.

  • Who are Laverock Therapeutics’s competitors?

    Sitryx, Carmine Therapeutics, Vir Biotechnology, ArsenalBio, and Progenra are some of the 93 competitors of Laverock Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process